Suggestions
David Klein
Co-Founder & CEO of Click Therapeutics
David Benshoof Klein is a healthcare innovator and entrepreneur with over 20 years of experience in the life science industry.14 He is the co-founder and CEO of Click Therapeutics, a company he established in 2012 to develop and commercialize software as prescription medical treatments.23
Klein coined the term "Digital Therapeutics" and has been instrumental in positioning Click Therapeutics as a market leader in software-based medical treatments.23 Under his leadership, the company has developed a broad pipeline of digital therapeutics across various therapeutic areas, including psychiatry, neurology, oncology, immunology, and cardiometabolic diseases.1
Career Highlights
- Co-founded Click Therapeutics in April 2012 and has been serving as CEO since then4
- Recognized by Goldman Sachs as one of the 100 Most Intriguing Entrepreneurs at the 2019 Builders + Innovators Summit2
- Named to the 2024 PharmaVoice 100 List, honoring the most inspiring people in the life sciences industry5
- Previously served as Managing Director at Opus Point Partners, where he created, financed, and operated several life science companies4
- Co-founder and owner of Eli Klein Gallery, America's leading Chinese contemporary art gallery14
Education
Klein's educational background includes:
- BA from Brandeis University (1996-2001)
- Attended Pardes Channa Agricultural School in Israel (1995-1996)
- Studied at California International School in Hong Kong (1994-1995)
- Attended Stuyvesant High School in New York City (1992-1994)34
David Benshoof Klein is known for his advocacy of rigorous development and high-quality evidence standards in digital therapeutics. His mission is to create safer and more efficacious treatments through the combination of software and drugs, believing that collaborations between tech and pharma will revolutionize healthcare and improve access to high-quality medical treatments globally.15
Highlights
CT-152 (Rejoyn™) is FDA Cleared!
I had the pleasure of representing Click Therapeutics, Inc. yesterday in our debut presentation at the J.P. Morgan Healthcare Conference, alongside my colleagues Randall Stanicky and Sarah Jackson, where we shared more on Click's many successes from this past year, as well as our excitement for the future. Top of mind for us is how the FDA draft guidance on prescription drug use-related software (#PDURS) will impact the future of patient care and serve to digitize Pharma pipelines - a change we believe the industry is finally ready for. For those interested in learning more about what we had to say, our team can be reached anytime at: [email protected] or [email protected] | #jpm2024
